Dose Responsive Effects of Subcutaneous Pentosan Polysulfate Injection in Mucopolysaccharidosis Type VI Rats and Comparison to Oral Treatment
Figure 3
GAG reduction in PPS-treated MPS VI rats.
(A) Total urine GAGs were significantly reduced in all PPS-treated MPS VI rat groups compared to untreated MPS control animals, regardless of the mode of administration. Subcutaneous treatment also significantly reduced urine GAGs compared to oral treatment. Tissue GAGs were significantly reduced only in the MPS VI rats treated with sc PPS. (B) kidney, (C) liver and (D) spleen. A dose responsive reduction was observed in the kidney and liver. *P<0.05 comparing treated to untreated MPS VI rats. ** P<0.05 comparing sc to oral treatment.